MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

Blood

Volumn 109, Issue 2, 2007, Pages 500-502

  Giles, Francis J ^a,c   Cortes, Jorge ^a   Jones, Dan ^a   Bergstrom, Donald ^b   Kantarjian, Hagop ^a   Freedman, Steven J ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXY GELDANAMYCIN; ABELSON KINASE; BCR ABL PROTEIN; CRK LIKE PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDROXYUREA; IMATINIB; NILOTINIB; PEGINTERFERON; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HUMAN; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

EID: 33846240316     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-05-025049     Document Type: Article

References (11)

1. Matthews N, Visintin C, Hartzoulakis B, Jarvis A, Selwood DL. Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev Anticancer Ther. 2006;6:109-120.
2. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004;10:262-267.
3. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006;66:6468-6472.
4. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev. 2006;16:92-99.
5. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A. 2005;102:11011-11016.
6. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
7. Georgakis GV, Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol. 2005;1:273-281.
8. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.
9. Singer CF, Hudelist G, Lamm W, et al. Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep. 2006;15:353-359.
10. Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinib failure. Blood. 2006;108:1421-1423.
11. Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006;66:1007-1014.